Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst

Key Points

• Brookline Capital Markets raised SAB Biotherapeutics’ Q3 2026 EPS forecast to a loss of $0.24 per share from $0.25, while projecting narrower losses in subsequent years and profitability of $0.48 per share in FY2029.
• SAB Biotherapeutics reported a quarterly loss of $0.28 per share, matching analyst expectations. The stock opened at $3.90, compared with a 52-week range of $1.85 to $5.15.
• Analyst sentiment remains broadly positive, with nine Buy ratings and an average target price of $12.00; institutional ownership stands at 7.82%, led by a significantly expanded stake from Perceptive Advisors.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) - Equities research analysts at Brookline Capital Markets upped their Q3 2026 earnings per share (EPS) estimates for SAB Biotherapeutics in a report released on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of ($0.24) per share for the quarter, up from their prior forecast of ($0.25). The consensus estimate for SAB Biotherapeutics' current full-year earnings is ($1.21) per share. Brookline Capital Markets also issued estimates for SAB Biotherapeutics' Q4 2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at $0.48 EPS.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.28).

Other equities research analysts also recently issued research reports about the company. Leerink Partners raised their price target on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, June 15th. Chardan Capital upped their price objective on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a "buy" rating in a report on Wednesday, June 17th. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Barclays initiated coverage on shares of SAB Biotherapeutics in a research report on Wednesday, June 24th. They issued an "overweight" rating and a $13.00 price objective on the stock. Finally, Wall Street Zen raised shares of SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a report on Monday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $12.00.

SAB Biotherapeutics Price Performance

SABS stock opened at $3.90 on Monday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $354.86 million, a PE ratio of -3.00 and a beta of 0.53. SAB Biotherapeutics has a 1-year low of $1.85 and a 1-year high of $5.15. The business's 50 day simple moving average is $3.68 and its 200 day simple moving average is $3.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new position in SAB Biotherapeutics during the 2nd quarter worth $421,000. Seven Fleet Capital Management LP bought a new stake in shares of SAB Biotherapeutics in the first quarter valued at about $1,915,000. DV Trading LLC acquired a new position in shares of SAB Biotherapeutics in the first quarter valued at about $1,532,000. Perceptive Advisors LLC grew its stake in shares of SAB Biotherapeutics by 700.8% in the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company's stock valued at $24,634,000 after acquiring an additional 5,628,533 shares in the last quarter. Finally, Bank of America Corp DE increased its position in SAB Biotherapeutics by 424.8% during the first quarter. Bank of America Corp DE now owns 55,697 shares of the company's stock worth $213,000 after acquiring an additional 45,084 shares during the period. 7.82% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting SAB Biotherapeutics

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: Brookline Capital Markets raised its FY2030 EPS estimate for SAB Biotherapeutics; the latest report adds to a series of upward revisions, including improved forecasts for fiscal 2027 and 2028 and a shift to projected profitability of $0.48 per share in FY2029. SABS FY2030 EPS Estimate Lifted by Brookline Capital Markets
• Positive Sentiment: Brookline also raised its Q3 and Q4 2026 EPS estimates to a loss of $0.24 per share from losses of $0.25, and improved its FY2027 estimate to a $0.95 loss from a $1.07 loss. These revisions suggest the firm expects losses to narrow faster than previously forecast. Brookline Capital Markets SAB Biotherapeutics estimates
• Neutral Sentiment: HC Wainwright reiterated its “Buy” rating and $10 price target, substantially above the recent trading level. However, its updated projections still call for losses of $1.21 per share in FY2026 and $0.60 in FY2027, compared with the current consensus FY2026 loss estimate of $1.19 per share. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright lowered its Q3 and Q4 2026 EPS estimates to losses of $0.29 and $0.31, respectively, and cut its FY2026 through FY2030 forecasts. The firm now expects a $0.48 loss in both FY2029 and FY2030, indicating a slower path to profitability than Brookline projects. HC Wainwright SAB Biotherapeutics estimates

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source